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Abstract
Frontocortical NMDA receptors are pivotal in regulating cognition and mood, are hypofunctional in schizophrenia, and may
contribute to autistic spectrum disorders. Despite extensive interest in agents potentiating activity at the co-agonist glycine
modulatory site, few comparative functional studies exist. This study systematically compared the actions of the glycine reuptake
inhibitors, sarcosine (40–200 mg/kg) and ORG24598 (0.63–5 mg/kg), the agonists, glycine (40–800 mg/kg), and D-serine (10–
160 mg/kg) and the partial agonists, S18841 (2.5 mg/kg s.c.) and D-cycloserine (2.5–40 mg/kg) that all dose-dependently
prevented scopolamine disruption of social recognition in adult rats. Over similar dose ranges, they also prevented a delay-
induced impairment of novel object recognition (NOR). Glycine reuptake inhibitors specifically elevated glycine but not D-serine
levels in rat prefrontal cortical (PFC) microdialysates, while glycine and D-serine markedly increased levels of glycine and D-
serine, respectively. D-Cycloserine slightly elevated D-serine levels. Conversely, S18841 exerted no influence on glycine, D-
serine, other amino acids, monamines, or acetylcholine. Reversal of NOR deficits by systemic S18841 was prevented by the
NMDA receptor antagonist, CPP (20 mg/kg), and the glycine modulatory site antagonist, L701,324 (10 mg/kg). S18841 blocked
deficits in NOR following microinjection into the PFC (2.5–10μg/side) but not the striatum. Finally, in rats socially isolated from
weaning (a neurodevelopmental model of schizophrenia), S18841 (2.5 and 10 mg/kg s.c.) reversed impairment of NOR and
contextual fear-motivated learning without altering isolation-induced hyperactivity. In conclusion, despite contrasting neuro-
chemical profiles, partial glycine site agonists and glycine reuptake inhibitors exhibit comparable pro-cognitive effects in rats of
potential relevance to treatment of schizophrenia and other brain disorders where cognitive performance is impaired.
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Introduction
The role of glutamatergic dysfunction in psychiatric disorders
is well established, and N-methyl-D-aspartate (NMDA) recep-
tors retain special interest because of their broad cortical and
subcortical distribution, localisation on GABAergic interneu-
rons and pyramidal cells, and key role in regulation of
neuroplasticity, cognition, epilepsy, mood and motor behav-
iour. Furthermore, the NMDA channel blocker, ketamine is
attracting interest as a fast-acting antidepressant which is
metabolised to (2S,6S;2R,6R)-hydroxynorketamine that acti-
vates AMPA receptors [1] and causes mTOR- and BDNF-
dependent increased dendritic arborisation in dopaminergic
neurons which may be beneficial to other mood disorders [2,
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s12035-020-01875-9) contains supplementary
material, which is available to authorized users.
* Kevin C.F. Fone
kevin.fone@nottingham.ac.uk
* Mark J. Millan
mark.millan@servier.com
1 School of Life Sciences, Queen’s Medical Centre, The University of
Nottingham, Nottingham NG7 2UH, UK
2 Centre for Therapeutic Innovation-CNS, Institut de Recherche
Servier, Centre de Recherches de Croissy, 125 Chemin de Ronde,
78290 Croissy-sur-Seine, France
Molecular Neurobiology
https://doi.org/10.1007/s12035-020-01875-9
3]. Furthermore, agents promoting NMDA activity are also of
potential use to treat Alzheimer’s disease, Parkinson’s disease,
autism spectrum disorders (ASDs), and schizophrenia [4, 5].
Glutamate activation of the NMDA receptor requires con-
current binding of glycine or, predominantly in the PFC, D-
serine at the glycine modulatory site [6–8]. Thus, pharmacolog-
ical modulation of the glycine site has been prioritised to restore
hypofunction by direct agonism, inhibition of enzymes regulat-
ing serine metabolism or increasing synaptic glycine by inhibi-
tion of glycine transporters [9–12]. Although glycine and D-
serine have been extensively characterised, it has proven very
hard to generate small molecule, positive modulators of the
glycine site. Recently, the partial agonists GLYX-13
(rapastinel) [13] and ((2S, 3R)-3-hydroxy-2-((R)-5-isobutyryl-
1-oxo-2,5-diazaspiro[3,4]octan-2-yl)butanamide) NYX-2925
[14] were shown to enhance hippocampal LTP and cognition
in rodent paradigms. Although the cyclic imidazolinone,
S18841 [15], was not developed clinically, this glycine site
partial agonist is a very useful ligand for exploitation in parallel
with the prototypical partial agonist D-cycloserine to identify
the functional roles of the glycine modulatory site and ascertain
underlying potentially beneficial therapeutic mechanisms. This
approach was supported by the current findings that unlike
other agents tested, S18841 did not significantly elevate
microdialysate glycine levels making it a particularly informa-
tive agent to examine the impact of partial agonism at the gly-
cine site on cognitive function.
NMDA receptor hypofunction is strongly implicated in the
pathogenesis of schizophrenia [16, 17]. Moreover, increased
levels of the endogenous NMDA receptor antagonists, N-
acetylaspartylglutamate (NAAG), and kynurenate, occur in
the cortex and hippocampus [18] along with decreased plasma
D-serine [19] but see [20] and glycine in schizophrenia, and
depletion of the latter correlates with severity of negative symp-
toms [21]. Genetic and functional studies suggest alterations in
the rate-limiting enzyme for D-serine synthesis, D-serine
racemase, and the major metabolising enzyme D-amino oxi-
dase particularly in the prefrontal cortex (PFC) may contribute
to NMDA receptor hypofunction in schizophrenia [16, 22]. D-
Cycloserine and the tetrapeptide glycine partial agonist, GLIX-
13, improve social behaviour in mice models of ASD [23] and
D-cycloserine alleviated anxiety, social and vocal communica-
tion changes in the valproate rat model of ASD [24] as well as
attenuating stereotype behaviour in 20 young ASD patients
[25], but there have been few other clinical trials.
Over 70 placebo-controlled clinical trials with glycine
modulatory site compounds (including glycine, D-serine, D-
cycloserine and sodium benzoate) often given as adjuncts to
antipsychotics have shown inconsistent and at best modest
improvement in negative symptoms or cognitive domains
[10, 17, 26]. Such inconsistent findings could be due to a
bell-shaped dose response effect; desensitisation with chronic
administration of glycine agonists, or muscarinic actions of
antipsychotics preventing any cognitive improvement (as
discussed fully later); or variation in the pharmacological ef-
fect of glycine agonists, partial agonists and GlyT1 inhibitors
used, a possibility investigated herein. In comparison, another
recent meta-analysis showed that NMDAmodulators (glycine
and D-serine) were more effective than amisulpiride, risperi-
done and olanzepine at reducing negative symptoms in ado-
lescents at clinical high risk for developing psychosis [27].
Therefore, such drugs may be of potential use for preventing
the transition of ultra-high-risk subjects to full-blown psycho-
sis and schizophrenia [28, 29]. They also warrant further in-
vestigation as a treatment for ASD, particularly if preclinical
evidence could identify unique pharmacological mechanisms
associated with any benefit.
GlyT1 inhibitors like sarcosine, ORG25935, and bitopertin
(RG1678), increase NMDA receptor-dependent hippocampal
LTP [30] and attenuate PCP-induced hyper-responsiveness to
d-amphetamine in rodent models [30]. A few studies have also
shown the impact of GlyT1 inhibitors on behaviour in animal
models for psychiatric disorders. The GlyT1 inhibitor, ALX-
5407, increased prepulse inhibition of acoustic startle (PPI) in
DAB/2 mice with naturally low PPI [31], ASP2535 reversed a
neonatal phencyclidine-induced impairment of NOR [32], and
ORG25935 reversed the attention deficit seen in the 5-choice
continuous performance task in a transcription factor specific-
ity protein 4 hypomorphic mouse model for bipolar disorder
and schizophrenia [33]. Further, bitopertin showed initial
promise against negative symptoms in phase II trials [34].
Although phase II/III clinical studies were disappointing [35,
36], recent add-on trials of the D-amino acid oxidase inhibitor,
sodium benzoate with the GlyT1 inhibitor, sarcosine, im-
proved cognitive and global functioning in patients with
schizophrenia [12], so clinical evaluation of drugs that rein-
force NMDA receptor activity remains of interest. The current
study was therefore performed to determine the key cortical
neurotransmitters involved in the cognitive effects of agents
that modify glycine function. This should, in turn, help iden-
tify reasons underlying the poor predictive translational value
of animal models for clinical trials in schizophrenia and help
identify potential new therapeutic targets to overcome cogni-
tive and social dysfunction in schizophrenia and other CNS
disorders such as ASD.
As discussed above, few studies have compared the utility
of glycine site direct agonists, partial agonists, and GlyT1
inhibitors, in relevant rodent models to clarify the potential
clinical utility of these mechanisms and novel agents to treat
schizophrenia. Accordingly, we compared the glycine modu-
latory site agonists (glycine, D-serine, D-cycloserine and
S18841) and GlyT1 inhibitors (sarcosine and ORG25935)
on microdialysis levels of glycine and D-serine and other neu-
rotransmitters thought to regulate cognition in the prefrontal
cortex (PFC) of rats [37]. These compounds were also com-
pared in three cognitive tasks: social recognition, novel object
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recognition (NOR) and an associative conditioned freezing
response (CFR) task (selected for translational relevance to
schizophrenia from consensus reviews [38, 39], and whose
predictive validity will be considered in the discussion). In
addition, we employed a microinjection procedure to examine
the role of the PFC in the action of S18841.
Finally, we examined the effect of S18841 in a
neurodevelopmental model, rearing rats in social isolation
from weaning, that produces behavioural and neurochemical
changes resembling schizophrenia [40, 41] including reduced
PFC volume [42, 43] and hippocampal expression of genes
involved in glutamate, GABA and dopamine neurotransmis-
sion [44]. This model is associated with an impairment in
NOR [44–47], CFR [45, 46, 48] and social interaction [49],
making it ideal for the current investigation.
Materials and Methods
Animals
Male Lister hooded rats (Charles River UK) were used for the
novel object recognition (NOR) and isolation studies, while
maleWistar rats (Charles River L’Arbresle, France) were used
for the social recognition and microdialysis studies. All rats
were housed in conventional open top cages with food and
water available ad libitum under 12 h light/dark cycle (lights
on 07.00 h) and constant temperature 21 ± 2 °C and humidity
55 ± 10%. All behavioural studies were performed between
08.00 and 16.00 h, and following every test, the apparatus
was thoroughly cleaned with 20% v/v ethanol and dried to
remove odour cues. All studies were performed using a blind
protocol, so that the observer was unaware of drug treatment.
Experiments were conducted in accordance with the Animals
(Scientific Procedures) Act, 1986 and ARRIVE guidelines
with approval of University of Nottingham Local Ethical
Committee (behaviour) or EU guidelines (microdialysis). All
efforts were made to minimise animal suffering, and the num-
ber of animals used.
Extracellular Amino Acids Levels by Microdialysis
Male Wistar rats (225–300 g) supplied by Charles River
(L’Arbresle, France) were housed in groups (3–4) with free
access to food and water. Rats were anaesthetised under chlo-
ral hydrate (400 mg/kg, i.p.) and a guide cannula implanted
above the PFC at coordinates: AP + 2.2, L ± 0.6 and DV − 0.2.
[50]. Five days later, a cuprophane CMA/11 probe (4 mm)
was implanted and perfused at 1 μl/min with a Ringer solution
(NaCl 147.2 mM; KCl 4 mM and CaCl2 2.3 mM buffered
with phosphate at pH, 7.3) for 150 min to obtain stable base-
line levels, and samples taken every 20 min thereafter for 3 h.
Amino acid levels were measured in 5 μl dialysate using
fluorimetric detection (ex 420 nm; em: 490 nm, FP2020plus,
Jasco, Bouguenais, France) after separation by linear gradient
chromatography (0% B to 40% B over 40 min where the
mobile phase was ammonium acetate (50 mM, pH = 6.8, plus
tetrahydrofurane (3%), and B was ammonium acetate
(50 mM, pH = 6.8) plus acetonitrile (60%)) using a reverse
phase column (Kromasil C18, 250 mm × 2.1 mm, particle
size, 5 μm, Cluzeau Info Labo, Courbevoie, France) main-
tained at 44 °C and a flow rate of 0.4 ml/min as detailed
elsewhere [51]. At the end of the experiment, sky blue was
perfused through the probe and rats killed by pentobarbital
overdose to verify correct probe placement by histology in
50 μm sections. Amino acid levels in fractional samples were
expressed as a percentage of the mean value during 90 min
baseline measurement immediately before treatment.
Social Recognition
Social recognition, a cortical-dependent workingmemory task
based on olfactory discrimination of a novel from a familiar
juvenile rat, considered relevant to dysfunction seen in psy-
chiatric disorders [52, 53], was examined in adult rats. The
procedure, described elsewhere [54, 55], evaluated the
promnesic actions of compounds on a scopolamine-induced
(1.25 mg/kg s.c.) deficit. Adult male Wistar rats were individ-
ually housed for 2 days before testing. On the test day, a
juvenile was placed into the home cage for a 5 min session.
A second 5 min session was performed immediately after the
first one with the same juvenile reintroduced (for evaluation of
the promnesic actions of ligands on a scopolamine-induced
(1.25 mg/kg s.c.) deficit of recognition). The time (s) spent
in active social investigation (i.e., the time spent by adult rat in
sniffing, following, biting, jumping and crawling over or un-
der the juvenile) during the first (T1) and the second (T2)
session was monitored. The difference “T2–T1” was calculat-
ed and dose-response curves produced.
Social Isolation
The social isolation paradigm extensively validated in our
laboratory [44–47, 56] produces a robust, reproducible behav-
ioural syndrome including phenotype changes relevant to
neurodevelopmental disorders with deficits in social behav-
iour and cognition such as schizophrenia, many of which are
reversed by treatment with existing antipsychotics [46, 49].
The ability of acute injection of S18841 to reverse deficits in
motor and cognitive behaviour was examined in this
neurodevelopmental model. Rats were weaned at postnatal
day (PND) 24, and half of each litter were housed either in
social groups (3–4 per cage, 50 × 33 × 26 cm) or alone (41 ×
24 × 20 cm) for the rest of the study. Isolated rats were housed
in the same holding room having auditory and olfactory con-
tact but no physical interaction with conspecifics. Rats were
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isolated for 5 weeks before undergoing a battery of behaviour-
al tasks, arranged in order of least to most aversive (to mini-
mise any sequential effect on subsequent tasks) at approxi-
mately 1-week intervals.
Locomotor Activity
Locomotor activity (ambulation and rearing) was measured
using infrared beams during a 1 h period as described before
and in detail in the supplementary information [49, 57].
Novel Object Recognition
NOR is a visual learning andmemory task that relies on innate
preference of rats for novelty. It does not require previous
training or re-enforcement [58] and is considered to have etho-
logical relevance to human declarative memory [53, 59] im-
paired in schizophrenia. Furthermore, a recent translational
study showed that the NOR discrimination ratio obtained in
rat studies is a valid analogue of the sensitivity of human
recognition memory in a visual-paired comparison task [60].
A 4 h inter-trial interval (ITI) prevents rats’ ability to discrim-
inate the novel from familiar object in our two-trial NOR task
[61] that has been thoroughly validated. Acute treatment with
dopamine D3 receptor antagonists, 5-HT6 antagonists and
mGluR2/3 agonists reverse this impairment, while D2 receptor
antagonists impair performance using a short ITI [49, 57, 61,
62], making it ideal choice to evaluate the effect of S14481.
During the social isolation rearing study, a 2 h ITI was used
with which group-housed vehicle-treated rats readily discrim-
inate the novel from the familiar object [57]. In studies inves-
tigating the effect of drugs on a delay-induced impairment of
NOR, a 4 h ITI was utilised so that normal, adult group-
housed vehicle-treated rats were unable to discriminate the
novel from the familiar object [54]. Twenty-four hours before
the test, rats were habituated to the arena (see “Locomotor
Activity” for details) for 1 h. On the test day, rats were briefly
reacclimatized to the arena for 3 min before being returned to
the home cage for 1 min. During the familiarisation trial, two
identical objects (plastic bottles, 8 cm high and 5 cm diameter,
covered in white masking tape) were placed in opposite cor-
ners of the arena (5 cm from the side and 10 cm from the end
wall). The rat was returned to the arena for 3 min, and explo-
ration of each identical objects was recorded with stop-
watches. After a 2 or 4 h ITI (in the social isolation and
dose-response studies, respectively), the rat was returned to
the arena with one familiar and one novel object (bottle
wrapped with 4 black stripes 1.2 cm in width). During this
second, choice, trial exploration of each object was recorded
for 3 min. Exploratory behaviour was defined as sniffing,
licking, touching and direct attention to the object with active
vibrissae while the nose is within 1 cm of the object. Climbing
on or chewing the object was not considered as exploration.
Object exploration time during the choice trial was used to
determine the discrimination ratio (time at novel–time at
familiar/total choice trial object exploration).
Conditioned Freezing Response
CFR is a well-characterised, species conserved, hippocampal,
amygdala and cortical dependent learning and memory task
[63] utilised to index long-term associative memory of emo-
tional based preference that is impaired in schizophrenia [64].
CFR is classically considered as part of the exemplary para-
digms to investigate acute threat within the negative valence
domain under the RDoC framework. However, the memory
component of this paradigm, as investigated in this study, is
clearly part of the cognitive system domain of the RDoCmatrix
highly pertinent to emotional memory and deficits thereof
are seen in ASD and schizophrenia [65]. CFR was performed
in a two-chamber shuttle box with light and dark sides (27 ×
25 × 25 cm), separated by an automated door (8 × 8 cm) and a
wire grid floor (PanLab, Slab, Barcelona, Spain) using a 3 day
test protocol described previously [45, 66]. On the first
(conditioning) day, rats received S18841 (2.5 or 10 mg/kg) or
vehicle (1 ml/kg s.c.) 30 min before being placed in the light
side of the chamber. The door opened after 30 s and latency to
cross into the dark side was recorded using a floor sensor which
closed the door (ShutAvoid, software v.1.8.2., Panlab S.L,
USA). After 30 s in the dark side, a 5 s conditioning stimulus
(CS, light and 3 kHz, 89 dB tone) was followed by the uncon-
ditioned stimulus (US, 1 s 0.4 mA footshock during the last
second of the CS) through the grid floor. A further two CS/US
were delivered at 55 s intervals. Time spent freezing (complete-
ly immobile except for respiration in a hunched posture with
inactive vibrissae) between shocks was recorded by stopwatch.
Twenty-four and 48 h post-conditioning, rats were returned to
the dark side for 300 s without CS/US and time spent freezing
recorded again as an index of associative learning and memory.
During the extinction trial (48 h post-conditioning), the CS
alone was presented after 300 s and freezing recorded for a
further 300 s. Behaviour was also recorded through a camera
in the roof of the CFR chamber using Ethovision (Noldus) to
enable re-assessment if required.
Microinjection for NOR
In order to ascertain the importance of glycine receptors in the
prefrontal cortex (PFC) in the cognitive effects of S14481, it
was delivered by microinjection into this area. The PFC was
selected because of the microdialysis data showing changes in
either serine or glycine overflow occurred therein with admin-
istration of all the glycine agonists, partial agonists and reuptake
inhibitors used herein. Lister hooded rats were anaesthetised
with isoflurane (3.5% induction and maintained with 2% in
33%O2 and 66%N2O), placed in a stereotaxic frame to implant
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cannulae as described before [54]. Two 22-gauge guide cannu-
lae, 1.5 mm apart projecting 3.5 mm, were implanted above the
PFC or in separate rats 5.0 mm apart projecting 5.0 mm above
the striatum (Plastics One) at the following coordinates from
bregma: PFC; AP + 3.0, L ± 0.7, DV − 2.3 and striatum; AP +
0.5, L ± 2.5, DV − 4.0 [50]. Stylets (Plastics One) placed in the
cannulae prevented occlusion. Rats were housed individually
and allowed to recover for at least 1 week and handled daily to
minimise stress associated with drug infusion. On the test day,
rats were lightly restrained, stylets removed and sterile 28-
gauge injectors (Plastics One) used to bilaterally infuse 1 μl
drug or vehicle over 2 min with an infusion pump (Harvard
Apparatus, Holliston, MA), 5 min before the NOR
familiarisation trial. After behavioural testing, brains were re-
moved and stored in paraformaldehyde for histological verifi-
cation of the injection from coronal brain sections according to
Paxinos and Watson [50].
Materials
S18841 (3-Hydroxy-4-imidazolidinone), glycine, D-serine,
D-cycloserine, sarcosine and ORG24598 were dissolved in
0.9% (w/v) saline, pH normalized where appropriate and
injected in a volume of 1 ml/kg s.c. 30 min prior to each task
except for glycine which was dosed at a volume of 4 ml/kg.
L701,324 (7-chloro-4-hydroxy-3-(3-phenoxy) phenyl-2(H)-
quinolinone, 5 mg/kg in 4 ml/kg) was suspended in distilled
water with a few drops of Tween 80. CPP (3-(2-
carboxypiperazin-4-yl)propyl-1-phosphonic acid, 10 mg/kg
in 1 ml/kg) was dissolved in 0.9% (w/v) saline and pH nor-
malised with NaOH. L701,324 and CPP were injected i.p.
45 min prior to the NOR task. For microinjection into the
PFC or striatum, S18841 was dissolved in artificial cerebro-
spinal fluid (aCSF) containing 10% w/v hydroxypropyl-β-cy-
clodextrin. The rat was lightly restrained and vehicle (1 μl/
side) or S18841 injected at a rate of 0.5 μl/min 5 min prior to
the behavioural analysis.
Statistical Analysis
In the social recognition task, the difference “T2–T1” was
calculated and dose-response curves for promnesic properties
analysed by one-way ANOVA followed by Dunnett’s test.
The time course of locomotor activity and rears and time spent
exploring each object during the NOR choice trial were
analysed using two-way repeated measures RM-ANOVA.
Total activity counts and object exploration and discrimination
ratio during NOR were analysed with two-way ANOVA (but
one-way ANOVA for delay-induced NOR impairment stud-
ies). Following ANOVA (P < 0.05 was considered significant
in all cases), Fishers LSD or Dunnett’s tests were used for post
hoc analyses. All statistical analyses were performed using
GraphPad Prism v7.0 for Windows (GraphPad Software,
San Diego, CA, USA) and SPSS (IBM SPSS Statistics v21,
USA), and all data shown are mean ± SEM. For microdialysis,
time-course effects of drugs on amino acid levels was
analysed by two-way ANOVA, with treatment as a between-
subjects factor and time a repeated measure, followed by
Dunnett’s post hoc tests. Dose effects of drugs were evaluated
by comparing the area under the curve during the first 180 min
after i.p. injection of the drug or vehicle and statistical analysis
was carried out by a two-way ANOVA followed by
Bonferroni’s post hoc tests.
Results
Effect of Glycine Modulatory Drugs on PFC Dialysate
Levels of Amino Acids and Monoamines in Freely
Moving Rats
Given the pivotal role of PFC function in the modulation of
working memory and the cognitive deficits seen in common
psychiatric disorders, we used microdialysis to ascertain any
common mode of action of the glycine-modifying drugs on
neurotransmitter release therein. In freely moving rats, com-
pared to vehicle, both glycine (F(1,19) = 306.7, P< 0.001) and
the two GlyT1 inhibitors (sarcosine F(1,18) = 710.3, P< 0.0001;
and ORG24598, F(1,29) = 38.62, P< 0.001) significantly in-
creased (by 700, 150 and 130% above basal) glycine in PFC
dialysates which peaked at 20 to 40 min (Fig. 1 a and c). In
contrast, glycine levels were unaffected by the glycine site ag-
onists, D-serine or D-cycloserine or by S18841. D-serine
(F(1,9) = 10.00, P = 0.0115) and D-cycloserine (F(1,10) = 42.99,
P< 0.001) were the only compounds to significantly elevate
PFC D-serine levels (Fig. 1 b and d). No compound changed
dialysate levels of glutamate, GABA, 5-HT or acetylcholine
and only glycine and sarcosine elevated dopamine while gly-
cine also elevated levels of noradrenaline (Table 1).
Effect of Glycine Modulatory Drugs on Disruption
of Social Recognition by Scopolamine
We next compared the ability of all the glycine-modifying
drugs to reverse a cholinergic-induced impairment of social
discrimination of a novel from a familiar juvenile rat, a
cortical-dependent workingmemory task to examine the func-
tional consequence of the microdialysis data in adult rats.
Social recognition was selected because of its perceived trans-
lational relevance to dysfunction in psychiatric disorders [53].
In the social recognition task with no intertrial delay, vehicle
rats investigated the juvenile rat significantly less in T2 than
T1, demonstrating social recognition memory (Fig. 2).
However, adults given scopolamine (1.25 mg/kg s.c.) prior
to T1 spent a similar time investigating the juvenile in T2
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and T1, indicative of impaired recognition memory compared
to vehicle controls. The glycine site agonists, glycine (Fig. 2a,
main effect of scopolamine, F(1,50) = 53.14, P< 0.001; gly-
cine, F(3,50) = 3.93, P = 0.0135 and an interaction, F(3,50) =
3.73, P = 0.0170), D-serine (Fig. 2b, scopolamine, F(1,52) =
24.32, P < 0.0001; D-serine, F(3,52) = 2.57, P = 0.0644 and
interaction, F(3,52) = 2.66, P = 0.045), D-cycloserine (Fig. 2c,
scopolamine, F(1,51) = 31.59, P < 0.0001; D-cycloserine,
F(3,51) = 5.93, P = 0.0015 and interaction, F(3,51) = 7.22, P =
0.0004), and S18841 (Fig. 2f, scopolamine, F(1,581) = 69.92,
P< 0.0001; S18841, F(5,81) = 7.76, P< 0.0001 and interac-
tion, F(5,81) = 6.85, P < 0.0001) and the GlyT1 inhibitors,
sarcosine (Fig. 2d, scopolamine, F(1,61) = 21.55, P< 0.0001;
sarcosine, F(4,61) = 2.94, P = 0.0274 and interaction, F(4,61) =
6.90, P = 0.0001) and ORG24598 (Fig. 2e, scopolamine,
F(1,62) = 45.08, P < 0.0001; ORG24598, F(4,62) = 6.48, P =
0.0002 and interaction, F(4,62) = 7.76, P < 0.0001) all reversed
the impairment in social recognition caused by scopolamine,
restoring the reduction in time spent exploring the juvenile
in T2. Of particular note for every compound, the lowest
Fig. 1 Effect of glycine modulatory site agonists and glycine transport
inhibitors on extracellular glycine (a and c) and D-serine (b and d) levels
in the prefrontal cortex of freely moving male Wistar rats. Microdialysis
samples were taken for 180 min at 20-min intervals following acute
systemic injection of S18841, D-cycloserine, ORG 24598, D-serine (all
s.c.), glycine and sarcosine (both i.p.). Data is expressed as percentage
change from a 40-min baseline taken prior to injection (mean ± SEM, n =
5–26). Basal levels of glycine and D-serine were 8.28 ± 1.07 and 0.90 ±
0.13 μM, respectively. Two-way ANOVA for a, b and c (not d) showed
significant main effects of drug (P = 0.001), time (P = 0.001) and an in-
teraction (P = 0.001). Significant two-way ANOVA was found in a:
(effect on glycine levels) for ORG 24598: main effect of time (P
< 0.001) and drug (P< 0.001) and interaction (P< 0.001); in b: (effect
on D-serine levels) for D-cycloserine: main effect of time (P< 0.001),
drug (P< 0.001) and interaction (P < 0.001) and D-serine: main effect of
time (P< 0.001), drug (P< 0.001) and interaction (P< 0.001); and in c:
(effect on glycine) for glycine: main effect of time (P< 0.001), drug (P
< 0.001) and interaction (P< 0.001) and sarcosine: main effect of time
(P < 0.001), drug (P< 0.001) and interaction (P< 0.001). *P< 0.001,
**P < 0.01, ***P < 0.001 between drug and vehicle at that time,
Bonferroni’s multiple comparisons post hoc test
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dose to significantly increase social discrimination was
lower than or equal to that shown to elevate glycine or
D-serine levels in PFC microdialysates (Table 2).
Furthermore, reversal of the recognition impairment oc-
curred irrespective of whether the drug elevated glycine
or D-serine, suggesting that either mechanism was ef-
fective, as is partial agonism at the glycine site.
Effect of Glycine Modulatory Drugs
on the Delay-Induced Impairment of Novel Object
Recognition
NOR is a visual learning and memory task considered to have
ethological relevance to human declarative memory [53, 59]
that is both PFC-dependent and impaired in schizophrenia,
a b
c d
e f
Fig. 2 Reversal of a scopolamine-induced deficit in social recognition in
Wistar rats by a glycine, bD-serine, cD-cycloserine, d sarcosine, eORG
24598 and f S18841. Data shown (T2-T1) is the time difference (s) in the
exploration by the adult of the juvenile rat between the second (T2) and
first (T1) trials. Values are means ± SEM, n = 5–13. Rats were sequen-
tially administered test drug (at doses indicated, s.c.) or vehicle (0.9% (w/
v) saline, 1 ml/kg) 30 min prior to T1. Two-way ANOVA showed a for
glycine: main effect of scopolamine (P< 0.001), glycine (P = 0.0135)
and an interaction (P = 0.0170); b D-serine: main effect of scopolamine
(P < 0.0001), D-serine (P = 0.0644) and interaction (P = 0.045); c D-
cycloserine: main effect of scopolamine (P < 0.0001), D-cycloserine
(P = 0.0015) and interaction (P = 0.0004); d sarcosine: main effect of
scopolamine (P< 0.0001), sarcosine (P = 0.0274) and interaction (P =
0.0001); e ORG 24598: main effect of scopolamine (P< 0.0001), ORG
24598 (P = 0.0002) and interaction (P < 0.0001); and f S18841: main
effect of scopolamine (P< 0.0001), S18841 (P< 0.0001) and interaction
(P < 0.0001). ***P< 0.001 between vehicle/scopolamine and vehicle/
vehicle; #P < 0.05, ##P < 0.01 and ###P < 0.001 between drug/
scopolamine and vehicle/scopolamine Newman-Keuls post hoc test
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and its selection is thoroughly considered in the discussion.
We therefore performed dose-response studies with all the
glycine-modifying compounds to establish their ability to im-
prove a time-delay-induced impairment in NOR.With vehicle
injection in all studies, rats were unable to distinguish the
novel from the familiar object in the choice trial (Fig. 3 a, c,
e, g and i). However, the highest two doses of every agonist or
glycine reuptake inhibitor increased the time spent exploring
the novel over the familiar object, and even the lowest dose
(2.5 mg/kg) of D-cycloserine produced a significant increase.
With glycine, D-serine and sarcosine (F(3, 44) = 2.709, P =
0.057, F(3, 44) = 7.45, P < 0.001, and F(3, 44) = 10.27, P
< 0.001, respectively), the significant increase in novel object
exploration was dose-related, while the improvement seen
with D-cycloserine (F(3, 44) = 6.518, P< 0.01) was similar at
all three doses and with ORG24598 (F(3, 44) = 8.23, P < 0.001)
only apparent at the highest two doses.
Analysis of the choice trial discrimination ratio data (Fig. 3 b,
d, f, h and j) from the same rats confirmed improvement in object
discrimination predicted from raw exploration times. In all
groups, the discriminated ratio was at or close to chance follow-
ing vehicle and significantly increased with glycine (F(3, 44) =
3.17, P< 0.05; P< 0.05 two highest doses), D-serine (F(3, 44) =
9.64,P< 0.001;P< 0.01 andP< 0.001with 40 and 160mg/kg,
respectively), D-cycloserine (F(3, 44) = 3.73, P< 0.05; P< 0.05
with all doses), sarcosine (F(3, 44) = 7.88, P< 0.001; P< 0.001,
highest dose only) and ORG24598 (F(3, 44) = 8.72, P< 0.001; P
< 0.01 and P< 0.05 at 2.5 and 5 mg/kg, respectively). Thus, as
with social recognition, the minimum dose to improve NORwas
equivalent to, or lower than, that found to elevate either PFC
glycine or D-serine in microdialysates (Table 2), consistent with
mechanistic association.
No dose of any drug caused a preferential exploration of
either object during the familiarisation trial (Table 3), although
with sarcosine ANOVA showed a significant (F(3, 44) = 10.27,
P< 0.001) location × drug interaction. Furthermore, only in the
D-serine group was there anymain effect of drug on total object
exploration time in the familiarisation trial (F(3, 44) = 2.98, P
< 0.05) and this was not dose-related. In all other groups, there
was no effect of drug treatment on total exploration in either
familiarisation or choice trials (Table 3). Therefore, alteration of
choice trial object exploration by all five drugs resulted from
redistribution of attention towards the novel object, consistent
with a specific effect on visual learning and memory and not a
reduction in attention to both objects.
Acute pretreatment with the glycine site partial agonist,
S18841 (0.63 to 10 mg/kg s.c.), reversed a time delay-
induced impairment in NOR (Fig. 4 a and b). With a 4 h
ITI, vehicle-treated rats were unable to distinguish the novel
from the familiar object in the choice trial (Fig. 4a) as expected
[54]. S18841 produced a dose-related restoration of preferen-
tial novel object exploration (Fig. 4a object × S18841; F(3,
40) = 3.02, P < 0.05), confirmed by the discrimination ratio
(Fig. 4b, F(3, 40) = 3.70, P < 0.05) being significantly (P
< 0.01) greater than vehicle with the highest dose (10 mg/kg).
There was no preference for either object and nomain effect of
drug treatment during the familiarisation trial (Table 4).
Similarly S18841 had no effect on total object exploration
during either the familiarisation (Table 4) or choice trials
confirming a specific pro-cognitive effect of S18841.
Prevention of the Pro-cognitive Effect of S18841
on NOR by Blockade of NMDA Receptors
To establish the downstream role of NMDA receptor activa-
tion in the effect of S18841 on recognition memory, we
showed that the glycine modulatory site antagonist,
L701,324, and the NMDA receptor antagonist, CPP,
completely prevented the reversal of impairment of NOR by
S18841 (Fig. 4 c and d). Akin to data in the dose-response
study, vehicle-treated rats were unable to discriminate novel
and familiar objects but S18841 (10 mg/kg) restored novel
Table 2 Comparison of the dose of each glycine modulatory site
agonist, partial agonist or GlyT1 inhibitor (GlyT1 I, as indicated in the
activity column) to significantly (a) elevate prefrontal cortex (PFC) gly-
cine and D-serine, (b) reverse scopolamine-induced impairment in social
recognition (taken from T2-T1 active social investigation time, s) and (c)
prevent the 4 h intertrial time delay-induced reduction in NOR (taken
from choice trial discrimination ratio, (novel-familiar/total object explo-
ration)). **P < 0.01 and ***P > 0.001 from vehicle control in that group
of rats Dunnett’s post hoc test following ANOVA. NOR = novel object
recognition, i.p. = intraperitoneal and s.c. = subcutaneous
Drug Activity Elevation in PFCmicrodialysate glycine or D-
serine dose mg/kg and route of injection
Reversal of scopolamine-impaired
social recognition dose mg/kg s.c.
Reversal of time-delay
reduction in NOR dose mg/kg i.p.
Glycine D-serine
Glycine Agonist 200 i.p.*** – 100** 160*
D-Serine Agonist – 160 s.c. *** 80** 40**
D-Cycloserine Partial agonist – 40 s.c. *** 0.63*** 2.5*
Sarcosine GlyT1 I 200 i.p.*** – 40** 200*
ORG24598 GlyT1 I 2.5 s.c.*** – 0.63*** 2.5**
S18841 Partial agonist – – 0.31 ** 10**
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object preference (Fig. 4c object × S18841; F(1, 40) = 12.29, P
< 0.01). Of note, co-treatment with either CPP or L701,324
prevented the S18841-induced reversal (object × CPP/
L701,324; F(2, 44) = 14.660, P < 0.001. Furthermore, the sig-
nificant increase in discrimination ratio in the S18841/vehicle
group (Fig. 4d, F(1, 44) = 6.79, P < 0.05) was abolished by
S18841/CPP and S18841/L701,324 combinations (F(2, 40) =
8.82, P< 0.01), the ratio being significantly less (P < 0.001
and P< 0.01, respectively) with CPP and L701,324 than with
vehicle/S18841 treatment. Both CPP and L701,324 reduced
total object exploration in the familiarisation trial (Table 3;
S18841; F(1, 44) = 4.56, P < 0.05, CPP/L701,324; F(1, 44) =
3.29, P < 0.05), but there were no significant changes in total
choice trial exploration. Despite total exploration being re-
duced, there was no object preference (Table 4) and neither
treatment effected the distribution of object exploration during
the familiarisation trial.
Reversal of Delay-Dependent Impairment of NOR
by Intra-PFC S18841
Consistent with the involvement of the PFC in the pro-
cognitive effects of S18841, bilateral PFC microinjection of
Table 3 Object exploration during familiarisation and choice trials with
glycine agonists and GlyT1 inhibitors, accompanying Fig. 3. Time (s,
mean (SEM)) spent exploring (from left to right) front and back object
and both objects during the (first) familiarisation trial and total time ex-
ploring both objects in the (second) choice trial in the novel object rec-
ognition test. For each glycine site agonist or glycine transporter-1 inhib-
itor, three doses (as stated) were compared to the effect of vehicle (s.c.)
given in a balanced quasi-random order over 4 weeks in five separate
groups of group-housed male Lister Hooded rats. Following D-serine
administration there was a significant main effect of drug treatment on
total object exploration during the familiarisation trial (P < 0.05). There
was no preference for the location of the object during the familiarisation
trial in any drug group, but following treatment with sarcosine there was a
significant location x drug interaction (P < 0.05). There was no significant
effect of any drug on total exploration during the choice trial (all
P > 0.05). *P < 0.05 from vehicle at that time point, Dunnett’s post hoc
following ANOVA
Familiarisation trial Choice trial
Drug Dose Front object (s) Back object (s) Total exploration (s) Total exploration (s)
Glycine (n = 12) Vehicle
40 mg/kg
160 mg/kg
800 mg/kg
5.5 (0.4)
6.9 (0.9)
7.0 (0.8)
6.9 (0.9)
5.7 (0.6)
8.0 (1.0)
6.2 (0.6)
6.3 (0.9)
11.2 (0.8)
14.9 (1.8)
13.2 (1.2)
13.2 (1.6)
10.8 (1.1)
10.9 (1.5)
12.1 (1.6)
13.7 (2.1)
D-Serine (n = 12) Vehicle
10 mg/kg
40 mg/kg
160 mg/kg
5.8 (1.0)
6.7 (0.7)
9.0 (0.9)
5.7 (0.9)
5.5 (0.8)
7.9 (0.8)
8.6 (1.3)
6.7 (0.6)
11.3 (1.7)
14.6 (1.2)
17.7 (2.2)*
12.3 (1.3)
12.1 (2.3)
9.8 (1.3)
9.9 (1.7)
11.7 (1.9)
D-Cycloserine (n = 11) Vehicle
2.5 mg/kg
10 mg/kg
40 mg/kg
7.5 (0.9)
6.3 (0.6)
5.5 (0.7)
6.5 (0.8)
7.6 (0.8)
6.5 (0.6)
6.7 (0.7)
6.9 (1.4)
15.1 (1.5)
12.7 (1.0)
12.2 (1.2)
13.5 (2.2)
7.5 (1.1)
9.7 (1.1)
8.6 (1.3)
11.8 (1.2)
Sarcosine (n = 12) Vehicle
40 mg/kg
80 mg/kg
200 mg/kg
6.0 (0.7)
4.5 (0.4)
5.1 (0.6)
5.5 (0.4)
4.1 (0.4)
4.8 (0.6)
5.3 (0.4)
5.6 (0.5)
10.1 (1.0)
9.3 (0.8)
10.3 (0.8)
11.1 (0.7)
9.2 (1.3)
7.8 (1.2)
8.7 (1.1)
7.9 (1.3)
ORG 24598 (n = 12) Vehicle
0.63 mg/kg
2.5 mg/kg
5 mg/kg
5.0 (0.8)
5.9 (1.0)
8.4 (1.2)
6.9 (0.9)
6.1 (0.8)
7.2 (1.0)
7.4 (1.1)
6.9 (0.7)
11.1 (1.5)
13.1 (1.6)
15.8 (2.1)
13.8 (1.3)
10.3 (2.0)
9.5 (1.7)
12.2 (1.4)
13.8 (1.5)
Fig. 3 Ability of glycine receptor agonists (a–f) and glycine reuptake
inhibitors (g–j) to reverse natural forgetting in a 4-h intertrial interval
novel object recognition paradigm. Comparison of the effect of glycine
(a and b, 40–800 mg/kg, 4 ml/kg), D-serine (c and d, 10–40 mg/kg, 1 ml/
kg), D-cycloserine (e and f, 2.5–40 mg/kg, 1 ml/kg), sarcosine (g and h,
40–200mg/kg, 1 ml/kg) andORG 24598 (i and j, 0.63–5mg/kg, 1 ml/kg)
injected s.c. 30 min prior to the familiarisation trial in Lister hooded rats
(n = 12 unless stated, data shown as mean ± SEM). a, c, e, g, i Actual
novel and familiar object exploration times (s) during the second choice
trial; *P< 0.05, **P< 0.01, ***P< 0.001 significantly different from
novel object in same treatment group, Bonferroni post hoc following
repeated measures ANOVA. b, d, f, h, j Derived discrimination ratio
(novel object exploration–familiar object exploration/total object explo-
ration); *P< 0.05, **P< 0.01, ***P< 0.001 significantly different from
vehicle control, Dunnett’s post hoc. In a, RM-ANOVA showed that the
object × glycine treatment interaction just failed to reach significance
(P = 0.057). b ANOVA showed a significant main effect of glycine treat-
ment (P< 0.05). c Significant object × D-serine interaction (P< 0.001). d
Significant main effect of D-serine (P < 0.001). e Significant object × D-
cycloserine interaction (P < 0.01, n = 11). f Significant effect of D-
cycloserine (P< 0.05, n = 11). g Significant object × sarcosine interaction
(P < 0.001). h Significant main effect of D-serine treatment (P < 0.001). i
Significant object × ORG 24598 treatment interaction (P < 0.001). j
Significant effect of ORG 24598 treatment (P < 0.001)
R
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S18841 reversed the delay-dependent impairment of NOR
(Fig. 4e, object × S18841; F(2, 29) = 4.11, P < 0.05) such that
rats given either dose spent significantly more (P< 0.01 and
P< 0.001) time exploring the novel object. PFC injection of
S18841 also increased the derived discrimination ratio (Fig.
4f, F(2, 29) = 4.68, P < 0.05) such that it was significantly
greater than vehicle (P < 0.05). In contrast, injecting S18841
into the striatum at the higher dose failed to enhance explora-
tion of the novel object (Fig. 4g) or alter the discrimination
ratio (Fig. 4h). Bilateral microinjections of S18841 into the
PFC or striatum had no effect on total object exploration dur-
ing either the familiarisation or choice trials (Table 4),
emphasising that improvement in visual recognition memory
was not due to changes in locomotor activity or inattention to
the objects during acquisition. In addition, irrespective of the
site of S18841 microinjection, it did not alter the distribution
of object exploration during the familiarisation trial (Table 4).
Histological analysis confirmed the site of the microinjections
in all rats (see online resource; Fig. S1).
Effect of S18841 upon Hyperactivity
of Isolation-Reared Rats
Commencing 5 weeks after weaning, rats underwent a
battery of behavioural tasks (Fig. 5a), the first being
placed in an unfamiliar chamber without drug adminis-
tration to confirm that isolation induced the expected
novelty-induced hyperactivity (supplementary Fig. S2A,
F(1, 48) = 16.70, P < 0.001). Isolation-reared rats showed
greater horizontal activity over time (time × housing;
F(11, 528) = 3.29, P < 0.001) when introduced to the
chamber compared to their group-housed littermates,
confirming development of the ‘isolation syndrome’. In
addition to hyperactivity, as expected, isolated rats
displayed significantly more rears over 1 h than group-
housed controls (online resource; Fig. S2B).
Six weeks after weaning, rats were pretreated with
S18841 (2.5 or 10 mg/kg) or vehicle before being re-
introduced into the chamber (Fig. 5a). As expected, the
socially isolated rats were hyperactive (Fig. 5b, F(1, 45) =
14.22, P < 0.001) but S18841 had no significant effect on
locomotor activity in group-housed or isolated rats.
Similarly, the increase in total rears in the isolated rats
(Fig. 5c, F(1, 45) = 16.42, P < 0.001) was unaltered by
S18841. This suggests that the partial glycine agonist
may have little effect on the augmentation of ventral teg-
mental dopaminergic activation of the nucleus accumbens
thought to contribute to the isolation-induced hyperactive
response to a novel environment.
Reversal of NOR Deficits in Isolation-Reared Rats
by S18841
The effect of S18841 on NOR in isolation-reared rats was
e x am i n e d t o a s c e r t a i n i f i t c o u l d r e v e r s e a
neurodevelopmental impairment in visual recognition
memory (Fig. 5 d and e). S18841 reversed the impairment
of NOR seen in isolation-reared rats, ANOVA showing an
object × S18841 treatment (F(2, 45) = 3.84, P < 0.05) and
object × housing × S18841 treatment (F(1, 45) = 22.89, P
< 0.001) interaction (Fig. 5d). Analysis of the derived dis-
crimination ratio (Fig. 5e) showed a significant main effect
of housing (F(1, 45) = 7.06, P < 0.05), confirming that this
index of NOR was also significantly greater in isolated rats
treated with either dose of S18841 (2.5 mg/kg; P < 0.01,
10 mg/kg; P < 0.001) than in vehicle-treated isolates, con-
s i s t e n t w i t h t h e d r ug - i nduc ed r ev e r s a l o f t h e
neurodevelopmental cognitive impairment. Rats did not
show any preferential exploration of the identical objects
in the familiarisation trial (Table 5), irrespective of housing
condit ion during development or drug treatment.
Furthermore, during both familiarisation and choice NOR
trials, total object exploration was greater in the isolated
groups but unaffected by drug treatment (Table 5). Thus,
the improvement in NOR produced by S18841 in
isolation-reared rats was not due to increased object atten-
tion during acquisition but a preferential improvement in
visual recognition memory.
Fig. 4 Restoration of a time-delay impairment (natural forgetting) in
novel object recognition by the partial glycine agonist, S18841, is
prevented by the glycine antagonist, L701,324, and the NMDA receptor
antagonist, CPP. S18841 (in a and b 0.63–10mg/kg, in c and d 10mg/kg)
or vehicle (1 ml/kg) injected s.c. 30 min prior to the familiarisation trial in
Lister hooded rats. CPP (20 mg/kg, 1 ml/kg), L701,324 (10 mg/kg, 4 ml/
kg) or vehicle (1 ml/kg) injected i.p. 20 min prior to the familiarisation
trial in c and d. The partial glycine agonist, S18841, delayed natural
forgetting in the novel object discrimination paradigm when discretely
injected into the prefrontal cortex (e and f) but not the striatum (g and h).
S18841 (2.5 μg or 10 μg/side) or vehicle (1 μl/side) injected 5 min prior
to the familiarisation trial in group-housed male Lister hooded rats. Data
presented as mean ± SEM. a, c, e, g Actual novel and familiar object
exploration time (s) during the second choice trial. b, d, f, h Derived
discrimination ratio (novel object exploration–familiar object
exploration/total object exploration). In a, RM-ANOVA showed a signif-
icant object × S18841 treatment interaction (P< 0.05), *P< 0.05 from
novel object in same treatment group, Bonferroni post hoc. b ANOVA
showed a significant effect of S18841 treatment (P< 0.05), **P< 0.01
from vehicle, Dunnett’s post hoc. c RM-ANOVA significant object ×
S18841 treatment (P < 0.01) and object × CPP/L701,324 interactions
(P < 0.001), ***P< 0.001 from novel object in same treatment group,
Bonferroni post hoc. d ANOVA showed a significant effect of S18841
treatment (P< 0.05) and a significant effect of CPP/L701,324 (P< 0.01),
**P< 0.01 from vehicle/vehicle; ++P< 0.01, +++P< 0.001 from S18841/
vehicle, Fishers LSD post hoc. e RM-ANOVA showed a significant ob-
ject × S18841 treatment interaction (P< 0.05), **P< 0.01, ***P< 0.001
from novel object in same treatment group, Bonferroni post hoc. f
ANOVA showed a significant effect of S18841 treatment (P < 0.05),
*P< 0.05 from vehicle, Dunnett’s post hoc. g RM-ANOVA no signifi-
cant object × S18841 treatment interaction (P = 0.510). h, ANOVA
showed a no significant effect of S18841 treatment (P = 0.531)
R
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Partial Reversal of CFR Deficits in Isolation-Reared
Rats by S18841
As reported previously, social isolation from weaning in-
duces deficits in contextual and conditioned associative
learning in the CFR task (Fig. 5 f and g) which is thought
to have translational relevance to negative valence sys-
tems in man. Neither isolation housing nor S18841 treat-
ment altered the latency of rats to cross from the more
aversive light to the dark side (data not shown) during
conditioning, indicating that alterations in CFR were not
confounded by changes in anxiety or locomotor activity.
However, freezing after each shock during conditioning
was significantly lower in isolates than group-housed rats
(Fig. 5f, housing; F(1, 45) = 1.57, P < 0.001) but increased
with each conditioning shock, as in group-housed con-
trols, and S18841 had no effect. Vehicle-treated isolated
rats froze for significantly less time than vehicle-treated
group-housed littermates (P < 0.01) when placed back in
the conditioning context 24 h later (Fig. 5g). ANOVA
showed a main effect of housing (F(1, 45) = 20.09, P
< 0.001) and S18841 (F(2, 45) = 7.77, P < 0.01), such that
isolates administered the highest dose of S18841 froze
significantly more (P < 0.01) than vehicle isolates and
S18841 restored freezing time in isolates to a level com-
parable to vehicle group-housed rats. In contrast, freezing
time was equivalent in all groups when rats were
reintroduced to the context at 48 h post-conditioning,
suggesting that extinction was unaltered by housing con-
dition or S18841. However, presentation of the CS 48 h
after conditioning increased freezing duration in group-
housed more than in isolated rats (Fig. 5g, F(1, 45) =
17.45, P < 0.001), but this was not reversed by S18841.
Discussion
Overall, the current study is the first comprehensive com-
parison of the glycine reuptake inhibitors, sarcosine and
ORG24598, the agonists, glycine and D-serine and the
partial agonists, S18841 and D-cycloserine on PFC
microdialysate amino acid and amine levels and cognitive
paradigms in normal rats and a neurodevelopmental mod-
el for schizophrenia. Both glycine and GlyT1 inhibitors
specifically elevated PFC glycine, while D-serine, and to
a lesser extent D-cycloserine, elevated D-serine levels,
whereas S18841 had no effect on either amino acid
(Table 2). All drugs dose-dependently prevented
scopolamine-induced impairment of social recognition in
adult rats and over similar dose-ranges attenuated a time-
delay-induced reduction of NOR (Table 2). Reversal of
NOR deficits by systemic S18841 was prevented by the
NMDA receptor antagonist, CPP, and the glycine modu-
latory site antagonist, L701,324, and the effect of S18841
on NOR replicated by microinjection into the PFC.
S18841 also reversed the deficit in NOR and impairment
Table 4 Object exploration during familiarisation and choice novel
object recognition trials accompanying Figs. 3 and 4. As detailed in
Table 2 legend, object exploration times (s) in the familiarisation and
choice trials during the novel object recognition task shown as mean
(SEM). In descending order, the groups show (1) the dose-response to
systemic administration of the glycine site partial agonist, S18841 alone,
(2) S18841 combined with administration of either the NMDA receptor
antagonist CPP or the glycine site antagonist L701,324, or S18841 given
by discrete microinjection into either the (3) medial prefrontal cortex
(PFC) or (4) the striatum. None of the drugs had any effect on either the
total object exploration or distribution of object exploration during the
familiarisation trial in any of the studies (all P > 0.05). Treatment with
CPP/ L701,324 significantly reduced total familiarisation trial exploration
(P < 0.05), and in that study, there was also an effect of S18841 treatment
(P < 0.05). *P < 0.05, **P < 0.01, ***P < 0.001 significantly different
from vehicle/vehicle group at that time point; +P < 0.05 significantly dif-
ferent from S18841/vehicle group at that time point, Fisher LSD post hoc.
PFC, prefrontal cortex
Dose of S18841 Familiarisation trial Choice trial
Front object (s) Back object (s) Total exploration (s) Total exploration (s)
Vehicle
0.63 mg/kg
2.5 mg/kg
10 mg/kg
(n = 11)
(n = 11)
(n = 11)
(n = 11)
8.9 (1.4)
7.8 (1.6)
6.6 (1.4)
5.8 (0.9)
8.5 (1.1)
7.8 (1.3)
7.0 (1.7)
6.2 (0.8)
17.4 (2.4)
15.6 (2.6)
13.6 (2.9)
12.0 (1.6)
13.3 (2.7)
13.8 (1.3)
12.5 (2.1)
12.2 (1.3)
Vehicle/Vehicle
S18841a/Vehicle
S18841a/CPPb
S18841a/L701324a
(n = 12)
(n = 12)
(n = 12)
(n = 12)
9.4 (0.8)
7.8 (0.9)
5.8 (0.9)
4.5 (0.9)
9.5 (1.0)
6.8 (0.7)
4.8 (0.6)
5.4 (0.7)
18.9 (1.6)
14.7 (1.5)*
10.7 (1.2)**
9.9 (1.3)*** +
13.6 (1.6)
10.5 (1.4)
8.3 (1.4)
6.6 (1.3)
Vehicle, PFC
2.5 μg/side
10 μg/side
(n = 16)
(n = 8)
(n = 8)
13.5 (1.6)
13.3 (1.2)
12.5 (1.7)
13.1 (1.9)
13.9 (2.2)
12.9 (1.7)
26.5 (3.0)
27.2 (3.0)
25.3 (3.2)
23.2 (1.2)
19.5 (3.0)
21.4 (2.8)
Vehicle, striatum
10 μg/side
(n = 8)
(n = 8)
18.2 (3.2)
17.8 (1.4)
20.4 (3.7)
17.8 (1.8)
38.5 (6.6)
35.6 (2.9)
21.6 (2.1)
21.6 (1.3)
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in contextual freezing in a conditioned associative learn-
ing task in rats reared in social isolation from weaning (a
neurodevelopmental model for schizophrenia). The poten-
tial relevance of these findings to cognitive impairments
seen in schizophrenia is discussed in detail below.
Modulation of Extracellular Amino Acids Levels
of in PFC
Consistent with extracellular glycine being tightly regulated
by GlyT1, and previous work with GlyT1 inhibitors in striatal
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microdialysates, sarcosine and ORG24598 elevated PFC
glycine [30, 51, 67–70] although striatal elevations may
be more marked than those in the PFC [37, 70].
Notably, doses of bitopertin achieving high GlyT1 oc-
cupancy in humans also elevated CSF glycine suggest-
ing translational pertinence of rat microdialysis studies
[71, 72]. Both ORG24598 and sarcosine specifically el-
evated glycine, without effecting D-serine, other amino
acids or acetylcholine, which could contribute to their
cognitive effects (Table 1). The only other change was a
modest increase in dopamine by sarcosine (Table 1).
These observations are important since, to our knowledge,
this is the first comprehensive neurochemical characterisation
of sarcosine, despite its extensive use as a specific “GlyT1 inhib-
itor” and an adjunctive agent in schizophrenia patients [12, 73,
74]. Lack of change in 5-HT is important given concerns about a
potential interaction with serotonergic transmission at a clinical
dose of 2 g [75] and a transient elevation of rat PFC 5-HTwith an
extremely high dose (2 g/kg p.o.) of sarcosine [76].
Glycine also elevated dialysate dopamine (and norepineph-
rine but not 5-HT), the rise being more pronounced than with
GlyT1 inhibitors, and completely selective (Table 1) versus
other amino acids [51]. It is unclear how glycine elevates
dopamine and norepinephrine levels, but this effect is unlikely
to involve NMDA receptor recruitment as other glycine site
agonists had no effect. One possibility might be a modification
of GABA interneuron input to dopaminergic pathways [77].
Increased PFC dopamine release may be advantageous to el-
evate cognitive and negative symptoms in man [37].
In a mirror image of glycine, D-serine markedly elevated
D-serine without affecting glycine [51] or other amines in-
cluding 5-HT, suggesting that the slight increase in 5-HT in
a previous dialysis study [76] resulted from an unselective
effect of the much higher dose (2 g/kg) used. Extracellular
cortical D-serine levels are dynamically regulated by
alanine-serine-cysteine transporters and reflect both neuronal
and glial origin [37, 78, 79].
A previous microdialysis study reported that systemic D-
cycloserine elevated PFC D-serine levels [80], both in wild-
type and serine racemase knockout mice, so it is unlikely to
reflect altered synthesis [81]. We confirm herein that D-
cycloserine modestly increased PFC dialysis D-serine, again
without affecting other amino acids or neurotransmitters
(Table 1). As proposed by Horio et al. [81], metabolism of D-
cycloserine to D-serine may account for this rise rather than any
effect on the glycine site, since neither S18841 (which cannot
be transformed into D-serine) nor the antagonist, L701,324,
affected D-serine. Moreover, D-serine was unaltered by the
other partial agonists. Finally, S18841 exerted no influence at
all on extracellular levels of any amino acid (including aspartate
and taurine, not shown) or neurotransmitter encouraging us to
focus on this pharmacological tool for further studies.
Importantly, demonstration of the highly selective action of
sarcosine, ORG24598, glycine (on glycine) and D-serine and
D-cycloserine (on D-serine) at doses relevant to those used as
adjuncts in schizophrenia clinical trials [10, 17, 26] provides
evidence of the likely common PFC neurochemical mecha-
nisms involved in their actions.
Reversal of Scopolamine-Impaired Social Recognition
and Time Delay Deficit in Novel Object Recognition
Scopolamine reproducibly impaired social recognition mem-
ory, and this was reversed (in a dose-related manner) by at
least two doses of the glycine modulatory site agonists glycine
and D-serine, partial agonists D-cycloserine and S18841, and
the GlyT1 inhibitors sarcosine and ORG24598. Although the
pathological relevance of scopolamine as a cognitive disruptor
can be questioned, it has been used as a translational tool to
investigate GlyT1 inhibitors in primates and man [82, 83].
Fig. 5 a Time course protocol for sequential assessment of locomotor
activity (LMA), novel object recognition (NOR) and conditioned freezing
in rats placed in individual cages (social isolation) or group-housed (lit-
termate controls) from weaning on post natal day 24. Effect of the partial
glycine agonist, S18841, on b locomotor activity and c number of rears
observed over 1 h in a novel arena, d novel and familiar object explora-
tion time (s) and e the derived discrimination ratio (novel object
exploration–familiar object exploration/total object exploration) during
the second choice trial of novel object recognition. Also in the condi-
tioned freezing task, the total freezing time (s) f after the first two of three
foot shocks during conditioning and g upon reintroduction into the cham-
ber 24 h after conditioning and again 48 h after conditioning both before
(Pre-Cue) and after presentation of the cue alone (Post-Cue), as indicated.
Rats were either group-housed (Social) or single housed (Isolate) from
weaning on post-natal day 24. S18841 (2.5 or 10 mg/kg s.c.) or vehicle
(1 ml/kg) was injected 30 min prior to b, c being placed in the arena for
1 h, d, e before the familiarisation trial and f, g before receiving foot shock
conditioning in the associative learning paradigm. Data expressed as
mean ± SEM, n = 10 per group. In b, RM-ANOVA showed a significant
main effect of housing (P< 0.001) but not drug treatment (P = 0.283). *P
< 0.05 from social/vehicle rats; ++P< 0.01 from social/10mg/kg S18841,
Fishers LSD. cRM-ANOVA revealed a significantmain effect of housing
(P < 0.001) but not drug treatment (P = 0.317). *P< 0.05 from social/
vehicle rats; +P< 0.05, ++P< 0.01 from social/10 mg/kg S18841, Fishers
LSD. d RM-ANOVA showed a significant object × S18841 treatment (P
< 0.05) and object × S18841 treatment × housing (P< 0.001) interaction,
***P< 0.001 from novel object in same treatment group, Bonferroni post
hoc. e ANOVA revealed a significant main effect of housing (P< 0.05)
and S18841 treatment (P< 0.001) and a significant housing × S18841
interaction (P< 0.001), *P< 0.05, ***P< 0.001 from social/vehicle. f
RM-ANOVA indicated a significant conditioning × housing interaction
(P < 0.05) and a main effect of housing (P< 0.001), *P< 0.05, ***P
< 0.001 significantly different from social/vehicle at that time point; +P
< 0.05, ++P< 0.01, +++P< 0.001 from social/10 mg/kg S18841, Fisher
LSD post hoc. g At 24 h post-conditioning ANOVA indicated a signifi-
cant main effect of housing (P< 0.001) and S18841 treatment (P< 0.05).
At 48 h, there was no main effect of housing or S18841 treatment pre-cue
but there was a main effect of housing post cue (P< 0.001), *P< 0.05,
**P < 0.01 from social/vehicle; +P < 0.05, ++P < 0.01, +++P < 0.001
from social/10 mg/kg S18841, ##P < 0.01 from isolate/vehicle Fisher
LSD post hoc
R
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All compounds also reduced a time-delay impairment of
NOR that was dose-related for glycine, D-serine sarcosine and
S18841. These pro-cognitive effects are consistent with pre-
vious studies. D-serine and NFPS improved performance in
time-delay impairment of social recognition [84].
Spontaneous NOR in mice and place recognition in rats and
mice was enhanced by D-cycloserine [85–87]. Supporting the
current data that sarcosine and ORG24598 attenuated natural
forgetting in NOR performance, glycine reuptake inhibitors
NFPS [84] TASP0315003 [88] and sarcosine all improved
NOR and NMDA antagonist-impaired social recognition.
Involvement of the NMDA Receptor and PFC
in S18841-Induced NOR Improvement
In this study, reversal of the time-delay-induced impairment of
NOR by acute S18841 was prevented by pre-treatment with
the glycine site antagonist, L701,324, and the NDMA receptor
antagonist, CPP, suggesting that NMDA receptor activation is
required for the action of S18841. Consistent with this pro-
posal, D-serine reversed the NOR impairment produced by
the NMDA antagonists, MK-801 [87, 89] or PCP [87, 90].
In primates, D-cycloserine improved performance in a vari-
able delayed response task in the MPTP model of
Parkinsonism [91] and reversed impairments in a visual delay
nonmatching-to-sample task caused by glycine site or NMDA
receptor antagonism [92]. Similarly, the partial glycine site
agonist, GLYX-13 (Rapastinel), restored a PCP-induced
NOR impairment [93]. Both sarcosine and the glycine reup-
take inhibi tor (R)-(N-[3-(4 ′- f luorophenyl)-3-(4 ′-
phenylphenoxy)propyl]) reversed an NMDA antagonist-
induced impairment of NOR in rats and mice [89, 90] congru-
ent with the proposal that glycine-induced enhancement of
NMDA receptor function mediates the reported pro-
cognitive effects.
Bilateral microinjection of S18841 into the PFC (but not
the striatum) dose-relatedly reversed intertrial delay-impaired
NOR. However, the role of the PFC in NOR is complex, such
that dopamine D2 and D3 receptor drugs have opposite effects
on performance when injected into the PFC [54, 94].
Furthermore, D-cycloserine injection into the prelimbic cortex
reversed scopolamine-induced amnesia in two olfactory
(odour discrimination and food preference) tasks [95], sug-
gesting that the cortex may be a target for the observed rever-
sal of muscarinic attenuation of social recognition reported
herein. Of note, serine racemase knockout (SR−/−) mice de-
velop neurons with reduced complexity, length and spine den-
sity of apical dendrites in the medial PFC and show impaired
NOR [96].
Restoration of Cognitive Performance but Not
of Locomotor Activity by S18841 in Isolation-Reared
Rats
Rats reared in isolation took longer to habituate to a novel
environment, but this hyperactivity, thought to reflect a
mesolimbic hyperdopaminergic state analogous to that in psy-
chosis [97], was unaffected by S18841. Current antipsychotics
reverse the isolation-induced hyperactivity, at least in part,
through antagonism of dopamine D2 receptors [46, 49, 98].
Glycine site ligands do not possess D2 affinity but may exert
antipsychotic properties by a contrasting mechanism or en-
hance the clinical actions of antipsychotic drugs (although
they have never actually been tested alone in patients).
Consistent with previous studies [44–47], isolates showed
a marked NOR deficit that was reversed by S18841, suggest-
ing that glycine site agonists can reduce premature forgetting
in this neurodevelopmental model of schizophrenia. Only one
study has examined the effect of a glycine modulatory com-
pound in isolation-reared rats. D-Cycloserine reversed a
Table 5 Object exploration during the familiarisation and choice trials
in the novel object recognition task in rat littermates reared from weaning
either as a group or in social isolation accompanying Fig. 5 in the
manuscript. As detailed in Table 2 legend, object exploration times (s)
in the familiarisation and choice trials (separated by a 2 h interval) during
the novel object discrimination task shown as mean (SEM), n = 10 per
group. Rats were injected with either S18841 (2.5 or 10mg/kg) or vehicle
(1 ml/kg) s.c. 30 min prior to start of task. During the familiarisation trial,
although there was no significant difference between the exploration of
the front and back object, there was a significant location × housing
(P < 0.01) and location × S18841 treatment (P < 0.05) interaction.
During both the familiarisation and choice trials, ANOVA showed a main
effect of housing (P < 0.05 and P < 0.01, respectively). However, post
hoc analysis revealed that the only significant differences were between
the group-housed (social) rats administered S18841 and the isolation-
reared rats, +P < 0.05, ++P < 0.01 significantly different from social/
10 mg/kg S18841 group during that trial, Fisher LSD post hoc
Housing Drug Familiarisation trial Choice trial
Front object (s) Back object (s) Total exploration (s) Total exploration (s)
Social
Social
Isolate
Isolate
Isolate
Vehicle
10 mg/kg
Vehicle
2.5 mg/kg
10 mg/kg
15.9 (1.5)
12.3 (2.0)
13.7 (1.1)
15.4 (1.6)
14.1 (1.9)
14.8 (2.1)
11.3 (2.1)
19.5 (1.4)
14.8 (1.5)
18.8 (1.8)
31.2 (3.5)
25.8 (3.0)
33.2 (1.4)+
30.2 (2.6)
32.9 (3.5)+
28.7 (1.7)
22.4 (2.3)
32.9 (2.2)++
29.8 (1.7)++
28.7 (2.4)+
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deficit in retention in a visual discrimination task [99]. In the
present CFR task, social isolation reduced contextual freezing
24 h post-conditioning and when the cue was presented 48 h
post-training, consistent with impaired associative memory
reported previously [45, 46, 48]. S18841 given prior to con-
ditioning attenuated the isolation-induced reduction in contex-
tual freezing. Interestingly, the contextual memory phase of
this task in rats is NMDA receptor dependent, being attenuat-
ed by MK-801 [66], consistent with the current hypothesised
mechanism of S18841.
General Discussion and Broader-Clinical Relevance
of the Present Observations
As a note of caution both social recognition and NOR tasks
rely on spontaneous preference for novelty and their predic-
tive validity to cognitive impairment in schizophrenia requires
further confirmation [39, 100, 101]. For instance, drugs with
different pharmacological mechanisms, such as α7-nicotinic
agonists and 5-HT6 receptor antagonists produced much
smaller improvements in cognition in schizophrenia clinical
trials than would have been predicted from preclinical data,
even in studies using disease models rather than normal ani-
mals. Nonetheless, in our hands, selective dopamine D2 recep-
tor antagonists impair social novelty discrimination and NOR
[54] consistent with the lack of effect or worsening of cogni-
tion seen with current antipsychotics in patients with schizo-
phrenia, while the dopamine partial agonist cariprazine re-
versed the isolation-rearing induced impairment in NOR [49].
Taken together, this study provides extensive, consistent
complimentary and neurochemical evidence that pharmaco-
logical modulation of glycine site activity on NMDA recep-
tors can improve cognitive dysfunction in rats, but similar
robust positive observations have not been reported in schizo-
phrenia trials using glycine site agonists [17, 26]. Poor trans-
lation may result from desensitisation of the glycine site as
seen with repeated D-cycloserine [102], producing NMDA
receptor internalisation [103] which might not occur with
acute administration used in most animal studies. Second,
the glycine full and partial agonists appear to have differential
affinity for the different NMDA receptor subunit composi-
tions found at pre- and post-synaptic sites in the cortex [104]
that could affect their relative clinical effectiveness. Thirdly,
the ability of glycine site agonists to facilitate symptom im-
provement may be impeded by antipsychotics with muscarin-
ic antagonism, such as clozapine and other atypicals, by op-
posing any pro-cognitive actions [94]. Interestingly, D-serine,
D-cycloserine and sodium benzoate all improve haloperidol-
induced bradykinesia in the rat by elevating nigrostriatal do-
pamine release, suggesting that they may also reduce
antipsychotic-induced extrapyramidal side effects [105].
Furthermore, they might be useful in the prodromal phase to
alleviate pre-diagnostic symptoms and, by improving social
cognition and social integration, decrease risk of transition to
psychosis [27–29, 37].
The present observations provide a framework to ex-
amine other agents, including novel glycine site ago-
nists, like Rapastinel [93] and NSX-2925 [14], the up-
take inhibitors TASP0315003 [88] and bitopertin [35,
36], D-amino acid oxidases inhibitors like sodium ben-
zoate [22, 106], and inhibitors of kynurenine amino-
transferase II all of which modify PFC glutamatergic
signalling [107, 108]. Furthermore, it would be interest-
ing to study agents acting at the neuronal alanine-serine-
cysteine-1 transporter which is implicated in the control
of extracellular D-serine and glycine [8, 109]. Finally,
one might compare the actions of BMS-466442, which
suppresses D-serine uptake [110], with those of
LuAE00527 which prevents D-serine release [79].
Although most research focusses on these agents enhanc-
ing cognition in psychiatric disorders [5, 111], current findings
are pertinent to disorders, like Alzheimer’s disease [112, 113],
where plasma D-amino acid oxidase levels correlate with cog-
nitive decline [114] but other work suggests that elevated
brain D-serine occurs in Alzheimer’s [112]. Furthermore, akin
to the fast antidepressant actions of ketamine, glycine site
partial agonists like Rapastinel may exert antidepressant ef-
fects via enhanced mTOR and BDNF signalling [1, 3].
Intriguingly, the major metabolites of ketamine are D-serine
racemase inhibitors [1–3], providing a direct link to the pres-
ent work. In addition, D-cycloserine and other glycine site
ligands may improve social cognition in ASDs and genetically
related Rett syndrome [115, 116]. Other indications under
consideration include drug abuse [117], amyotrophic lateral
sclerosis [22], chronic pain [118] and facilitation of
psychosocial-cognitive behavioural therapies for anxiety dis-
orders [119].
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